NewSquare Capital’s Nektar Therapeutics NKTR Stock Holding History

NewSquare Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-267	Closed	-$71K	–	413
2020 Q1	$71K	Buy	+267	New	+$82.6K	0.01%	158
2019 Q3	–	Sell	-267	Closed	-$142K	–	326
2019 Q2	$142K	Hold	267	–	–	0.03%	129
2019 Q1	$134K	Hold	267	–	–	0.03%	126
2018 Q4	$131K	Hold	267	–	–	0.03%	120
2018 Q3	$244K	Hold	267	–	–	0.05%	108
2018 Q2	$195K	Hold	267	–	–	0.04%	110
2018 Q1	$425K	Hold	267	–	–	0.09%	93
2017 Q4	$239K	Hold	267	–	–	0.05%	103
2017 Q3	$96K	Hold	267	–	–	0.02%	115
2017 Q2	$78K	Hold	267	–	–	0.02%	115
2017 Q1	$94K	Hold	267	–	–	0.02%	116
2016 Q4	$49K	Hold	267	–	–	0.01%	148
2016 Q3	$69K	Hold	267	–	–	0.02%	144
2016 Q2	$57K	Hold	267	–	–	0.01%	158
2016 Q1	$55K	Hold	267	–	–	0.02%	161
2015 Q4	$67K	Hold	267	–	–	0.02%	136
2015 Q3	$44K	Hold	267	–	–	0.01%	153
2015 Q2	$50K	Hold	267	–	–	0.01%	153
2015 Q1	$44K	Hold	267	–	–	0.01%	155
2014 Q4	$62K	Hold	267	–	–	0.02%	140
2014 Q3	$48K	Hold	267	–	–	0.02%	162
2014 Q2	$51K	Hold	267	–	–	0.02%	152
2014 Q1	$48K	Hold	267	–	–	0.02%	143
2013 Q4	$45K	Hold	267	–	–	0.02%	124
2013 Q3	$42K	Hold	267	–	–	0.02%	117
2013 Q2	$46K	Buy	+267	New	+$41K	0.02%	119

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

NewSquare Capital's NKTR Position: Q2 2020 in Review

NewSquare Capital sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 267 shares — an estimated $71K sold.

NewSquare Capital first reported a position in NKTR in Q2 2013 and held it in 26 quarters. The position peaked at $425K in Q1 2018. 259 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

NewSquare Capital reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
NewSquare Capital sold 267 Nektar Therapeutics shares in Q2 2020, an estimated $71K.
NewSquare Capital first reported a position in Nektar Therapeutics in Q2 2013 and held it in 26 quarters.
NewSquare Capital's Nektar Therapeutics position peaked at $425K in Q1 2018.
259 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on NewSquare Capital's 13F filing for Q2 2020, filed 5 Aug 2020.